Eligible subjects deemed by the treating physician to have sufficient severity to merit treatment of either their lateral canthal lines (LCL) or perioral rhytids (PR) or both will be treated with Princess® RICH at the Baseline visit and at week 3 and 6.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
102
Princess® RICH is injected into lateral canthal lines and/or perioral rhytids
MaRa-Medical Aesthetic Research Academy
Graz, Austria
Medizinische Universität-Klinikum für Dermatologie und Venerologie
Graz, Austria
YUVELL
Vienna, Austria
Effectiveness of Princess® RICH to correct fine lines on the face including lateral canthal lines (LCL) and perioral rhytids (PR)
Percentage of responders at week 8 Responder is defined as at least "improved" versus baseline in the fine lines of lateral canthal lines (LCL) and/or perioral rhytids (PR) assessed with the GAIS (Gloabel Aesthetic Improvement Scale) Global aesthetic improvement can be rated as 'very much improved', 'much improved', 'improved', 'no change' or 'worse
Time frame: Week 8 compared to Baseline
Effectiveness of Princess® RICH to correct fine lines on the face including lateral canthal lines (LCL) and perioral rhytids (PR)
Percentage of responders at week 12 and 16.
Time frame: Week 12 and 16 compared to Baseline
Ability of Princess® RICH to improve skin hydration
Change from baseline at weeks 3, 6, 8, 12 and 16 in skin hydration. Skin hydration is measured using a corneometer device.
Time frame: Week 3, 6, 8, 12 and 16 compared to Baseline
Ability of Princess® RICH to improve skin tone
Changes from baseline at weeks 3, 6, 8, 12 and 16 in skin tone. Skin tone is measured using a cutometer device.
Time frame: Week 3, 6, 8, 12 and 16 compared to Baseline
Ability of Princess® RICH to improve skin elasticity
Change from baseline at weeks 3, 6, 8, 12 and 16 in skin elasticity. Skin elasticity is measured using a cutometer device.
Time frame: Week 3, 6, 8, 12 and 16 compared to Baseline
Subject satisfaction with treatment
Subject satisfaction with treatment at weeks 8, 12 and 16. Satisfaction with the treatment will be graded using one of the following categories: "Very unsatisfied", "Unsatisfied", "Neither unsatisfied nor satisfied", "Satisfied", or "Very satisfied".
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Week 8, 12 and 16